» Articles » PMID: 23400111

Identification and Insilico Analysis of Retinoblastoma Serum MicroRNA Profile and Gene Targets Towards Prediction of Novel Serum Biomarkers

Overview
Publisher Sage Publications
Specialty Biology
Date 2013 Feb 13
PMID 23400111
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Retinoblastoma (RB) is a malignant tumor of the retina seen in children, and potential non invasive biomarkers are in need for rapid diagnosis and for prognosticating the therapy. This study was undertaken to identify the differentially expressed miRNAs in the serum of children with RB in comparison with the normal age matched serum, to analyze its concurrence with the existing RB tumor miRNA profile, to identify its novel gene targets specific to RB, and to study the expression of a few of the identified oncogenic miRNAs in the advanced stage primary RB patient's serum sample. MiRNA profiling was performed on 14 pooled serum from children with advanced RB and 14 normal age matched serum samples, wherein 21 miRNAs were found to be upregulated (fold change ≤ -2.0, P ≤ 0.05) and 24 to be downregulated (fold change ≥ +2.0, P ≤ 0.05). Furthermore, intersection of 59 significantly deregulated miRNAs identified from RB tumor profiles with that of miRNAs detected in serum profile revealed that 33 miRNAs had followed a similar deregulation pattern in RB serum. Later we validated a few of the miRNAs (miRNA 17-92) identified by microarray in the RB patient serum samples (n = 20) by using qRT-PCR. Expression of the oncogenic miRNAs, miR-17, miR-18a, and miR-20a by qRT-PCR was significant in the serum samples exploring the potential of serum miRNAs identification as noninvasive diagnosis. Moreover, from miRNA gene target prediction, key regulatory genes of cell proliferation, apoptosis, and positive and negative regulatory networks involved in RB progression were identified in the gene expression profile of RB tumors. Therefore, these identified miRNAs and their corresponding target genes could give insights on potential biomarkers and key events involved in the RB pathway.

Citing Articles

Molecular pathways in glioblastoma-derived stem cells to identify effective drug agents: A bioinformatics study.

Mirzaei T, Sheikholeslami S, Bereimipour A, Jalili A, Zali A, Sharbati S J Family Med Prim Care. 2022; 11(6):2856-2864.

PMID: 36119333 PMC: 9480797. DOI: 10.4103/jfmpc.jfmpc_1436_21.


Comprehensive Analysis of Serum Small Extracellular Vesicles-Derived Coding and Non-Coding RNAs from Retinoblastoma Patients for Identifying Regulatory Interactions.

Manukonda R, Yenuganti V, Nagar N, Dholaniya P, Malpotra S, Attem J Cancers (Basel). 2022; 14(17).

PMID: 36077715 PMC: 9454787. DOI: 10.3390/cancers14174179.


Review: New horizons in retinoblastoma treatment: an updated review article.

Azimi F, Mirshahi R, Naseripour M Mol Vis. 2022; 28:130-146.

PMID: 36034735 PMC: 9352364.


Applications of Non-Coding RNAs in Patients With Retinoblastoma.

Fernandez-Diaz D, Rodriguez-Vidal C, Silva-Rodriguez P, Paniagua L, Blanco-Teijeiro M, Pardo M Front Genet. 2022; 13:842509.

PMID: 35432447 PMC: 9008704. DOI: 10.3389/fgene.2022.842509.


miR-340 Promotes Retinoblastoma Cell Proliferation, Migration and Invasion Through Targeting WIF1.

Li K, Han F, Wu Y, Wang X Onco Targets Ther. 2021; 14:3635-3648.

PMID: 34113129 PMC: 8187089. DOI: 10.2147/OTT.S302800.


References
1.
Reid G, Kirschner M, van Zandwijk N . Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2010; 80(2):193-208. DOI: 10.1016/j.critrevonc.2010.11.004. View

2.
Kumar M, Erkeland S, Pester R, Chen C, Ebert M, Sharp P . Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 2008; 105(10):3903-8. PMC: 2268826. DOI: 10.1073/pnas.0712321105. View

3.
Vaksman O, Stavnes H, Kaern J, Trope C, Davidson B, Reich R . miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2010; 15(7):1593-602. PMC: 3823203. DOI: 10.1111/j.1582-4934.2010.01148.x. View

4.
Sahu S, Banavali S, Pai S, Nair C, Kurkure P, Motwani S . Retinoblastoma: problems and perspectives from India. Pediatr Hematol Oncol. 1998; 15(6):501-8. DOI: 10.3109/08880019809018311. View

5.
Radhakrishnan V, Kashyap S, Pushker N, Sharma S, Pathy S, Mohanti B . Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology. 2012; 119(7):1470-7. DOI: 10.1016/j.ophtha.2012.01.029. View